The long-term future outlook for AstraZeneca remains broadly favorable among institutional healthcare analysts, buoyed by a robust pipeline of oncology drugs, expanding cardiometabolic therapies, and continuous global clinical trial advancements. While patent expirations, drug pricing regulatory pressures, and clinical trial setbacks present standard pharmaceutical risks, the company's diversified revenue streams and global market penetration support steady long-term growth projections.